Literature DB >> 22430195

An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.

Stefan Tasler1, Roland Baumgartner, Delphine Behr-Roussel, Stephanie Oger-Roussel, Diane Gorny, Francois Giuliano, Peter Ney.   

Abstract

The relaxant effect of an aryloxypropanolamine β3-adrenoceptor agonist on carbachol pre-contracted human detrusor muscle strips was evaluated and compared with literature results from reference compounds of similar mode of action, including mirabegron. A significant relaxation was observed for rac-4-{2-hydroxy-3-[1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino]propoxy}-2-(hydroxymethyl)phenol which was similar to that exerted by mirabegron. In order to allow for a thorough discussion of results in comparison to reference compounds, their affinity, selectivity and efficacy as hβ3-AR agonists have been evaluated and discussed thoroughly. A ranking of hβ3-AR agonists by relative efficacy resulted in the closest analogy to the order of relaxation potential, with only the relaxant effect of mirabegron not reflecting its excellent relative efficacy as such.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430195     DOI: 10.1016/j.ejps.2012.03.001

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

1.  How β3 -adrenoceptor-selective is mirabegron?

Authors:  Martin C Michel
Journal:  Br J Pharmacol       Date:  2016-02       Impact factor: 8.739

2.  Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism.

Authors:  Iris Lim; Russ Chess-Williams
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-04-21       Impact factor: 3.195

3.  Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate.

Authors:  Ru Huang; Yuhan Liu; Anna Ciotkowska; Alexander Tamalunas; Raphaela Waidelich; Frank Strittmatter; Christian G Stief; Martin Hennenberg
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

Review 4.  Drug therapy of overactive bladder--what is coming next?

Authors:  Karl-Erik Andersson
Journal:  Korean J Urol       Date:  2015-10-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.